BioCryst, HHS extend peramivir agreement for 31 days BioCryst Pharmaceuticals disclosed that it and the U.S. Department of Health and Human Services mutually agreed to extend their agreementís current expiration date of February 28 for 31 days. The new expiration date is changed to March 31. The extension of the agreement will allow ongoing stability testing of peramivir to continue beyond the current contract expiration date. All other terms and conditions of the agreement remain unchanged.
News For BCRX From The Last 14 Days
Check below for free stories on BCRX the last two weeks.